Ibogaine - Mindcure
Alternative Names: IBOGAINE – MSYNTH-001; MC-106; MC-808Latest Information Update: 28 Apr 2026
At a glance
- Originator MINDCURE
- Class Analgesics; Antipsychotics; Drug withdrawal therapies; Ethers; Heterocyclic compounds with 4 or more rings; Indoles; Neuropsychotherapeutics; Rauwolfia alkaloids; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; NMDA receptor antagonists; Opioid receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Neuropathic pain; Traumatic brain injuries
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in CNS-disorders in Canada
- 28 Apr 2026 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada
- 28 Apr 2026 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in Canada